Panobinostat (Panobinostat)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other antineoplastic agents

Included in the formulation
  • Faridak
    capsules inwards 
    Novartis Pharma AG     Switzerland
    • АТХ:

    L.01.X.X.42   Panobinostat

    Pharmacodynamics:

    Inhibits histone deacetylase, which leads to apoptosis followed by death of tumor cells.

    Pharmacokinetics:

    After oral ingestion, up to 21% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 2 hours. The connection with plasma proteins is 90%.

    Metabolism in the liver.

    The half-life is 37 hours. Elimination with feces and kidneys.

    Indications:

    It is used to treat metastatic and inoperable melanoma.

    ICD-10

    II.C81-C96.C90.0   Multiple myeloma

    II.C43-C44.C43.9   Malignant melanoma of skin, unspecified

    Contraindications:

    Severe renal and hepatic insufficiency, simultaneous administration with inhibitors or inductors of CYP3A isoenzyme, pregnancy and lactation, age under 18, individual intolerance.

    Carefully:

    Glucose-galactose malabsorption.

    Pregnancy and lactation:

    Recommendations for FDA - Category X. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, 20 mg 3 times a week. The duration of treatment is determined individually.

    The highest daily dose: 20 g.

    The highest single dose: 20 mg.

    Side effects:

    Respiratory system: interstitial pneumonitis.

    Hemopoietic system: hemolytic anemia.

    The cardiovascular system: vasculitis, myocarditis, angiopathy, cardiomyopathy, bleeding.

    Digestive system: nausea, vomiting, diarrhea.

    Musculoskeletal system: arthritis, rhabdomyolysis.

    Dermatological reactions: leukocytoclastic vasculitis, psoriasis, photosensitivity.

    Sense organs: blepharitis, iritis, conjunctivitis, retinopathy.

    urinary system: glomerulonephritis.

    Reproductive system: degenerative changes in epithelial cells of the testes, ovaries and vagina.

    Allergic reactions.

    Overdose:

    Increased side effects.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Monitoring of liver and kidney function.

    During treatment and within 3 months after its termination it is recommended to use reliable methods of contraception.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up